KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD

By sjmartinez • December 25, 2023

Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2023 Dec 21:S0272-6386(23)00883-1. doi: 10.1053/j.ajkd.2023.09.003. Epub ahead of print. PMID: 38142396.

Tags: Chronic kidney disease, commentary, diabetes, evidence-based recommendation, GLP-1 RAs, guideline, guideline implementation, Nephrology, nephrology best practices, ns-MRAs, Publications, SGLT2 inhibitors

Hyperparathyroidism Secondary to Burosumab Treatment

Nguyen MK, Bandaru D, Nguyen MK. Hyperparathyroidism Secondary to Burosumab Treatment. Cureus. 2025 Aug 7;17(8):e89569. doi: 10.7759/cureus.89569. PMID: 40922882; PMCID: PMC12413978.

A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes

Tuttle KR, Kornowske LM, Jones CR, Reynolds CL, Alicic RZ, Daratha KB, Neumiller JJ, Duru OK, Nicholas SB, Norris KC, Pavkov ME; CURE-CKD Consortium. A[...]

Acute Renal Failure Due to Amyloidosis Associated With Intravenous Heroin Use

Malchira R, Shye M, Konanur R, Sidhu H, Zuckerman J. Acute Renal Failure Due to Amyloidosis Associated With Intravenous Heroin Use. Cureus. 2025 Jul 27;17(7):e88860.[...]